REDWOOD CITY, Калифорния (PRWEB) 29 июня 2020
АльтруБио Инк. http://www.altrubio.com, a clinical stage biotech company, has announced the presentation of AbGn-107 at the 2020 ASCO GI Cancer Symposium in January 24, 2020. AbGn-107 is an antibody-drug conjugate (ADC) that selectively targets a glycoepitope expressed on various gastrointestinal tumors. This dose-escalation Phase 1 study, led by renowned oncologist Dr. Andrew Ko of the University of California San Francisco, was conducted in patients with chemo-refractory locally advanced, recurrent, or metastatic gastric, pancreatic, colorectal or biliary cancer. AbGn-107 showed a well-tolerated safety profile and acceptable PK profile, as well as preliminary signs of efficacy including several patients with prolonged disease control. The ongoing cohort expansion phase was initiated focusing on enrollment of patients with high expression of this glycoepitope target to further evaluate the safety and efficacy of this ADC.
About AbGn-107.
AbGn-107, an antibody equipped with AltruBio’s proprietary linker-payload, targets novel tumor-associated antigens on the surface of certain gastrointestinal (GI) cancers including stomach, biliary system, pancreas, colon and rectum. The targeting antibody is conjugated with a potent toxin through a cleavable linker which could only be cleaved inside the tumor cells. AbGn-107 demonstrated an excellent antitumor efficacy in at least six established xenograft tumor models and a favorable safe profile in NHP toxicity studies. AbGn-107 binds to approximately 40-50% of pancreatic, gastric and biliary cancers and 20-25% of colorectal cancers.
About GI cancers
Pancreatic cancer is the third-leading cause of death from cancer in the United States, with a 5-year survival rate of about 6%, the lowest rate among all cancer types. Gastric cancer is the sixth most common cancer in the world and the third leading cause of cancer death worldwide. Colorectal cancer is the third most common cancer in the world. While the death rate from colorectal cancer is declining, it still remains the second most common cause of cancer-related death in the world. These sobering statistics highlight the need for more effective therapies and strategies that can improve the survival and quality of life of patients diagnosed with each of these malignancies.
Об AltruBio Inc. (http://www.altrubio.com)
AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’ pipeline includes two clinical stage product candidates: (i) Neihulizumab (AbGn-168H) an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and (ii) AbGn-107, an antibody-drug conjugate (ADC) employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. AbGn-107 has demonstrated encouraging results in chemo-refractory gastric, pancreatic, colorectal and biliary cancers.
Примечание к прогнозным заявлениям
Заявления, сделанные в этом пресс-релизе, не являющиеся историческими фактами, являются прогнозными заявлениями по смыслу Закона о реформе судебных разбирательств по частным ценным бумагам 1995 года. Такие слова, как ожидает, полагает, намеревается и подобные выражения, предназначены для обозначения прогнозных заявлений. Фактические результаты могут существенно отличаться от тех, которые прогнозируются в любом прогнозном заявлении. В частности, существует ряд важных факторов, которые могут привести к тому, что фактические результаты будут существенно отличаться от ожидаемых, например, способность Компании привлекать дополнительный капитал и риски, связанные со способностью Компании инициировать и включать пациентов в запланированные клинические испытания. Вы не должны чрезмерно полагаться на какие-либо прогнозные заявления. Компания не принимает на себя никаких обязательств по обновлению каких-либо прогнозных заявлений в результате появления новой информации, будущих событий или разработок, за исключением случаев, предусмотренных законом.
Поделиться статьей о социальных сетях или электронной почте:
